###begin article-title 0
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
###end article-title 0
###begin title 1
Aims
###end title 1
###begin p 2
###xml 135 142 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
###end p 2
###begin title 3
Methods and results
###end title 3
###begin p 4
###xml 590 593 590 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 795 796 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 861 864 846 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 878 880 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 935 936 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 952 959 928 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 1122 1129 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Ninety-eight patients with coronary artery disease (CAD) taking either clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD) or prasugrel 60 mg LD/10 mg MD were genotyped for variation in six CYP genes. Based on CYP genotype, patients were segregated into two groups: normal function (extensive) metabolizers (EM) and reduced function metabolizers (RM). Plasma active metabolite concentrations were measured at 30 min, 1, 2, 4, and 6 h post-LD and during the MD period on Day 2, Day 14, and Day 29 at 30 min, 1, 2, and 4 h. Vasodilator-stimulated phosphoprotein (VASP) and VerifyNowtrade mark P2Y12 were measured predose, 2, and 24 +/- 4 h post-LD and predose during the MD period on Day 14 +/- 3 and Day 29 +/- 3. For clopidogrel, active metabolite exposure was significantly lower (P = 0.0015) and VASP platelet reactivity index (PRI, %) and VerifyNowtrade mark P2Y12 reaction unit (PRU) values were significantly higher (P < 0.05) in the CYP2C19 RM compared with the EM group. For prasugrel, there was no statistically significant difference in active metabolite exposure or pharmacodynamic response between CYP2C19 EM and RM. Variation in the other five genes demonstrated no statistically significant differences in pharmacokinetic or pharmacodynamic responses.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 170 172 170 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Variation in the gene encoding CYP2C19 in patients with stable CAD contributes to reduced exposure to clopidogrel's active metabolite and a corresponding reduction in P2Y12 inhibition, but has no significant influence on the response to prasugrel.
###end p 6
###begin title 7
Introduction
###end title 7
###begin p 8
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C1">1</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C2">2</xref>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C1">1</xref>,<xref ref-type="bibr" rid="EHP157C2">2</xref></sup>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C3">3</xref>
###xml 479 480 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C3">3</xref></sup>
###xml 558 560 558 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C4">4</xref>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C6">6</xref>
###xml 570 573 570 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C4">4</xref>&#8211;<xref ref-type="bibr" rid="EHP157C6">6</xref></sup>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
The standard treatment for patients with acute coronary syndrome includes a combination of dual-antiplatelet therapy, aspirin, and a thienopyridine, which has proven to be efficacious in reducing the rate of recurrent cardiac events including stent thrombosis.1,2 Clopidogrel, the most commonly prescribed thienopyridine, and prasugrel, currently under clinical development, are both orally administered prodrugs that, after absorption, must be converted to an active metabolite.3 The active metabolites inhibit platelet aggregation via antagonism of the P2Y12 receptor.4-6
###end p 8
###begin p 9
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C8">8</xref>
###xml 489 490 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C8">8</xref></sup>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C9">9</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C10">10</xref>
###xml 707 711 707 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C9">9</xref>,<xref ref-type="bibr" rid="EHP157C10">10</xref></sup>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
Recently, we reported greater and faster P2Y12 receptor-mediated platelet inhibition with prasugrel loading dose (LD) 60 mg, maintenance dose (MD) 10 mg compared with clopidogrel 600 mg LD, 75 mg MD owing to a more efficient generation of prasugrel's active metabolite in aspirin-treated patients with stable coronary disease.7 Consistent with the literature, more patients had high residual platelet reactivity following clopidogrel administration than following prasugrel administration.8 Platelet inhibition is closely related to levels of active metabolite formation, and a poor pharmacodynamic response to clopidogrel is most likely primarily caused by differences in absorption or metabolism, or both.9,10
###end p 9
###begin p 10
###xml 405 413 405 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4/5</italic>
###xml 415 421 415 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2B6</italic>
###xml 458 465 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C11">11</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C13">13</xref>
###xml 480 485 480 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C11">11</xref>&#8211;<xref ref-type="bibr" rid="EHP157C13">13</xref></sup>
###xml 941 949 941 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4/5</italic>
###xml 954 960 954 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2B6</italic>
###xml 990 997 990 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 1002 1008 1002 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C14">14</xref>
###xml 1010 1012 1010 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C14">14</xref></sup>
###xml 1183 1185 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C15">15</xref>
###xml 1183 1185 1183 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C15">15</xref></sup>
The metabolic pathways for clopidogrel and prasugrel have some key differences. Approximately 85% of a clopidogrel dose is hydrolysed by esterases to an inactive metabolite, which cannot be converted to the active metabolite. The remaining clopidogrel is available to be converted to the active metabolite in a process requiring two sequential cytochrome P450 (CYP)-dependent steps with contribution from CYP3A4/5, CYP2C9, CYP1A2 in one step, and CYP2B6 and CYP2C19 in both steps.11-13 In essence, the esterase pathway competes with the CYP pathway for prodrug, and anything that slows the formation of the active metabolite may 'shunt' prodrug to the esterase pathway. Prasugrel, on the other hand, is hydrolysed by esterases into an intermediate precursor of the active metabolite. This intermediate is then oxidized to the active metabolite in a single CYP-dependent step by any one of the four CYP enzymes (with major contributions from CYP3A4/5 and CYP2B6 and minor contributions from CYP2C19 and CYP2C9).14 Formation of the prasugrel active metabolite may thus be mediated by any of the four CYP enzymes, and based on previous studies, they appear to compensate for each other.15
###end p 10
###begin p 11
###xml 328 336 328 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4/5</italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C15">15</xref>
###xml 630 632 630 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C15">15</xref></sup>
The differences in metabolism suggest that factors which reduce the activity of a CYP enzyme might lead to decreased formation of clopidogrel's active metabolite but would not affect the formation of prasugrel's active metabolite. This hypothesis is supported by the observation that co-administration of ketoconazole, a potent CYP3A4/5 inhibitor, did not affect the overall exposure to prasugrel's active metabolite or the associated pharmacodynamic response, whereas co-administration of ketoconazole with clopidogrel resulted in decreased exposure to clopidogrel's active metabolite and the associated pharmacodynamic response.15
###end p 11
###begin p 12
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C10">10</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C16">16</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C20">20</xref>
###xml 250 258 250 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C10">10</xref>,<xref ref-type="bibr" rid="EHP157C16">16</xref>&#8211;<xref ref-type="bibr" rid="EHP157C20">20</xref></sup>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
Emerging data suggest that variation in the genes encoding CYP enzymes associated with decreased CYP enzyme activity are associated with an altered pharmacodynamic and, in healthy volunteers, pharmacokinetic response to clopidogrel but not prasugrel.10,16-20 Therefore, we assessed the hypothesis that variation in the function of individual CYP enzymes, especially CYP2C19, would affect generation of the active metabolite and the corresponding pharmacodynamic response under LD/MD conditions in aspirin-treated patients with coronary artery disease (CAD).
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects and study design
###end title 14
###begin p 15
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C21">21</xref>
###xml 599 601 599 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C21">21</xref></sup>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB1">1</xref>
###xml 639 646 639 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="EHP157TB1">1</xref></italic>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
The present study was a prespecified part of a randomized, double-blind, double-dummy, two-arm parallel-group study comparing platelet inhibition of prasugrel 60 mg LD/10 mg MD vs. clopidogrel 600 mg LD/75 mg MD conducted in adult male and female patients with stable CAD.7 Subjects were not required to participate in the genetic sample collection to participate in the main study. Therefore, only subjects who signed a specific informed consent document for genotyping were included in these analyses (98 of 110 patients in the primary study). Medications capable of inhibiting CYP enzyme function21 were taken by 17 out of 98 patients (Table 1). The genotyping and associated clinical data were anonymized using a one-way, state-of-the-art encryption algorithm. The study was performed according to ethical principles based on the Declaration of Helsinki and was approved by local ethical review boards.
###end p 15
###begin p 16
Concomitant medication capable of inhibiting CYP P450 enzyme function
###end p 16
###begin p 17
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
CYP, cytochrome P450; n, number of patients.
###end p 17
###begin title 18
Genetic methodology
###end title 18
###begin title 19
DNA isolation and genotyping
###end title 19
###begin p 20
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C22">22</xref>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C22">22</xref></sup>
###xml 437 466 437 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2C19, 2B6, 2C9, 3A5, 3A4, 1A2</italic>
###xml 621 631 621 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*17</italic>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C23">23</xref>
###xml 632 634 632 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C23">23</xref></sup>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB2">2</xref>
###xml 688 696 688 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Table&#160;<xref ref-type="table" rid="EHP157TB2">2</xref></italic>
###xml 224 229 <span type="species:ncbi:9606">Human</span>
DNA was isolated from peripheral blood samples anticoagulated with ethylenediaminetetraacetic acid using the Gentra Puregene DNA Isolation Kit (Qiagen, Hilden, Germany). Genotyping was performed with the Affymetrix Targeted Human Drug Metabolizing Enzyme and Transporter (DMET) 1.0 Assay (Affymetrix, Santa Clara, CA, USA).22 47 genetic variants were measured by the DMET 1.0 Assay, comprising 53 alleles for the six CYP genes analysed (2C19, 2B6, 2C9, 3A5, 3A4, 1A2). One additional allele, not available on the chip, was measured by polymerase chain reaction (PCR)/restriction fragment length polymorphism data (RFLP): CYP2C19*17.23 A total of 48 genetic variants comprising 54 alleles (Table 2) was therefore obtained by combining DMET 1.0 and PCR/RFLP data.
###end p 20
###begin p 21
Cytochrome P450 genes
###end p 21
###begin p 22
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1 11 1 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*17</italic>
###xml 192 197 <span type="species:ncbi:9606">human</span>
aCYP2C19*17 allele measured by conventional polymerase chain reaction followed by restriction fragment length polymorphism analysis. All remaining alleles genotyped by the Affymetrix Targeted human drug-metabolizing enzymes and transporters (DMET) 1.0 Assay (Affymetrix, Santa Clara, CA, USA).
###end p 22
###begin p 23
CYP450, cytochrome P450.
###end p 23
###begin title 24
Classification based on predicted metabolic phenotype
###end title 24
###begin p 25
###xml 261 269 261 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C24">24</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C25">25</xref>
###xml 445 450 445 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C24">24</xref>,<xref ref-type="bibr" rid="EHP157C25">25</xref></sup>
###xml 521 548 521 548 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://www.cypalleles.ki.se">http://www.cypalleles.ki.se</uri>
To assess the effect of CYP genetic variation on the generation of prasugrel and clopidogrel active metabolite and subsequent pharmacodynamic response, individual variants of six CYP genes known to be involved in the metabolism of the two drugs were classified a priori according to their predicted metabolic phenotypes (normal, increased, or reduced enzymatic function). This classification was defined according to literature-based predictions24,25 using the established common consensus or 'star allele' nomenclature (http://www.cypalleles.ki.se).
###end p 25
###begin p 26
###xml 92 106 92 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*1A/*1A</italic>
###xml 373 380 373 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 491 501 491 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*17</italic>
###xml 593 603 593 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*17</italic>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C24">24</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C25">25</xref>
###xml 752 757 752 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C24">24</xref>,<xref ref-type="bibr" rid="EHP157C25">25</xref></sup>
###xml 797 803 797 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 867 868 867 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB3">3</xref>
###xml 861 868 861 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="EHP157TB3">3</xref></italic>
The combination of two alleles comprises a genotype and the various genotypes (for example, CYP2C19*1A/*1A) for each of the six CYP genes were placed in one of the following categories: extensive metabolizer (EM), defined as two alleles conferring normal or near-normal activity and reduced metabolizer (RM), defined by at least one reduced-function allele. In the case of CYP2C19, individuals with no alleles conferring decreased activity and at least one allele known to enhance activity (CYP2C19*17) were grouped with the EMs. Individuals with an allele conferring decreased activity and a CYP2C19*17 were categorized as unknown. For CYP3A5, individuals with only one allele conferring decreased activity have been found to have near-normal activity24,25 and were therefore categorized as EMs. CYP3A5 RMs were defined as having two reduced function alleles. Table 3 contains a summary of observed genotypes and their corresponding functional categories (predicted phenotypes) used for analyses.
###end p 26
###begin p 27
Genotyping results
###end p 27
###begin p 28
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
n, Number of subjects; CYP, cytochrome P450; EM, extensive metabolizer; RM, reduced metabolizer.
###end p 28
###begin title 29
Assessment of the active metabolites
###end title 29
###begin p 30
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
Plasma concentrations of the prasugrel active metabolite (R-138727) and clopidogrel active metabolite (R-130964) were analysed in samples obtained at 30 min, 1, 2, 4, and 6 h post-LD and during the MD period on Day 2, Day 14, and Day 29 at 30 min, 1, 2, and 4 h post-MD as previously described.7
###end p 30
###begin title 31
Pharmacodynamic assessment of platelet activity
###end title 31
###begin p 32
###xml 265 267 261 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 445 446 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 445 446 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 620 621 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 646 647 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 680 686 676 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1)</sub>
###xml 693 705 689 701 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1 + ADP)</sub>
###xml 711 717 707 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1)</sub>
###xml 666 725 662 721 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="33">PRI % = [(cMFI<sub>(PGE1)</sub> &#8722; cMFI<sub>(PGE1 + ADP)</sub>)/cMFI<sub>(PGE1)</sub>] &#215; 100%</p>
###xml 666 725 662 721 <disp-quote xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="33">PRI % = [(cMFI<sub>(PGE1)</sub> &#8722; cMFI<sub>(PGE1 + ADP)</sub>)/cMFI<sub>(PGE1)</sub>] &#215; 100%</p></disp-quote>
###xml 735 738 731 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 1002 1004 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C26">26</xref>
###xml 1002 1004 989 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C26">26</xref></sup>
###xml 1048 1050 1035 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Blood samples were collected into one-tenth volume of 3.2% trisodium citrate from the patients at baseline, 2, and 24 h post-LD and at Day 14 +/- 3 and Day 29 +/- 3, both before that day's MD. The vasodilator-stimulated phosphoprotein (VASP) assay, a measure of P2Y12 function, was performed using a commercially available method according to the manufacturer's specifications (Biocytex Platelet VASP kit, Marseille, FR) as previously described.7 The platelet reactivity index (PRI, %) was calculated from the corrected mean fluorescence intensity (cMFI) following incubation of the platelets with either prostaglandin E1 alone or prostaglandin E1 + ADP as follows: PRI % = [(cMFI(PGE1) - cMFI(PGE1 + ADP))/cMFI(PGE1)] x 100%The VerifyNowtrade mark P2Y12 assay (VN-P2Y12, Accumetrics, San Diego, CA, USA) is a whole-blood, point-of-care, light transmission-based optical detection assay that measures platelet-induced aggregation in a single-use disposable cartridge containing fibrinogen-coated beads.26 Results from the device are reported as P2Y12 reaction units (PRU) on a continuous scale from 0 upward. The VN-P2Y12 assay was performed on Day 1 at baseline (predose), 2, and 24 +/- 4 h post-LD and predose during the MD period on Day 14 +/- 3 and Day 29 +/- 3.
###end p 32
###begin p 33
###xml 14 20 14 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1)</sub>
###xml 27 39 27 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1 + ADP)</sub>
###xml 45 51 45 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PGE1)</sub>
PRI % = [(cMFI(PGE1) - cMFI(PGE1 + ADP))/cMFI(PGE1)] x 100%
###end p 33
###begin title 34
Statistical analyses
###end title 34
###begin p 35
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 388 399 388 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 &#8722;&#8734;</sub>
###xml 805 816 798 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 &#8722;&#8734;</sub>
###xml 1234 1246 1216 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0 &#8722; &#8734;</sub>
###xml 1400 1402 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C27">27</xref>
###xml 1400 1402 1375 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C27">27</xref></sup>
###xml 1575 1578 1550 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
The primary a priori hypothesis, to evaluate the effect of genetic variation in CYP2C19 on exposure to active metabolite and subsequent platelet aggregation pharmacodynamic responses following treatment with prasugrel or clopidogrel, was investigated. Initially, a linear model testing for interaction between genetic group (EM, RM) and the exposure to active metabolite, the mean log AUC0 -infinity was employed. The log transformation for area under curve (AUC) was used for data normalization. As the interaction model does not specify which drug treatment or genetic group is responsible for the significant effect, if a significant interaction was observed, further comparisons of genetic effect in each of the treatment groups would be undertaken. For the pharmacokinetic analyses, the mean log (AUC0 -infinity) of the EM was compared with that of the RM within each treatment group by estimating two contrasts (prasugrel-EM vs. prasugrel-RM and clopidogrel-EM vs. clopidogrel-RM) using a linear model with body weight as a covariate. The statistical significance was assessed via a two-sided test at the 0.05 alpha level. Prasugrel-EM was also compared with clopidogrel-EM in a similar manner. Analysis was not performed on AUC0 - infinity at MD since pharmacokinetic parameters were derived from a population-based model that included a component to account for differences between LD and MD.27 For the pharmacodynamic analyses, the mean of the EM group was compared with that of the RM group within each treatment group, and for each pharmacodynamic endpoint [VerifyNowtrade mark (PRU) and VASP (PRI)], by estimating two contrasts (prasugrel-EM vs. prasugrel-RM and clopidogrel-EM vs. clopidogrel-RM) using a similar linear model as in the pharmacokinetic analyses with baseline pharmacodynamic values and body weight as covariates.
###end p 35
###begin p 36
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2B6</italic>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 181 188 181 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
Subsequent analyses investigated the contribution of CYP2B6, CYP2C9, CYP1A2, and CYP3A5 to pharmacokinetic and pharmacodynamic responses to either of the thienopyridines. As in the CYP2C19 analysis, the contrasts between EMs and RMs for each gene and within each treatment arm (prasugrel or clopidogrel) were estimated using a linear model with body weight as a covariate.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 38
###begin p 39
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB4">4</xref>
###xml 271 278 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="EHP157TB4">4</xref></italic>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Of the 110 patients, 98 participating in the main study consented to genetic testing, 51 in the prasugrel group, and 47 in the clopidogrel group. This genetic subpopulation of patients had similar demographic and clinical characteristics to the overall study population (Table 4).7
###end p 39
###begin p 40
Demographics and baseline characteristics
###end p 40
###begin p 41
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
n, number of patients; SD, standard deviation. Body weight is measured in kilograms, age is measured years. TABR Genetic Subgroup: those patients in TABR who provided a sample for genetics.
###end p 41
###begin title 42
Genotyping results
###end title 42
###begin p 43
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB3">3</xref>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="EHP157TB3">3</xref></italic>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
The overall genotyping success rate was 98.8% with <1.2% genotypes unable to be called (Table 3). CYP2C19, CYP2C9, and CYP3A4 had a 100% genotyping success rate with all alleles determined for all patients for these genes.
###end p 43
###begin p 44
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="EHP157TB4">4</xref>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="EHP157TB4">4</xref></italic>
###xml 116 143 116 143 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://www.cypalleles.ki.se">http://www.cypalleles.ki.se</uri>
###xml 210 233 210 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5, CYP2C19, CYP2C9</italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2B6</italic>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 402 409 <span type="species:ncbi:9606">patient</span>
The frequencies of predicted metabolic phenotypes were similar to the published Caucasian frequencies (Table 4; see http://www.cypalleles.ki.se). The frequency of RM was sufficient to complete the analyses for CYP3A5, CYP2C19, CYP2C9, and CYP2B6. However, the observed frequency of RM for CYP3A4 and CYP1A2 was too low to support the statistical analyses with no RM patients for CYP3A4 and only one RM patient observed for CYP1A2.
###end p 44
###begin title 45
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
Relationship between pharmacokinetics and CYP2C19
###end title 45
###begin p 46
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 450 457 450 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 469 470 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F1">1</xref>
###xml 481 490 481 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures&#160;<xref ref-type="fig" rid="EHP157F1">1</xref></italic>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F2">2</xref>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="fig" rid="EHP157F2">2</xref></italic>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 812 819 812 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
CYP2C19 EM/RM and PK interaction was evaluated first using linear model and was found statistically significant. In prasugrel-treated patients, there was no relationship between exposure to its active metabolite and CYP2C19-predicted metabolizer status (P = 0.6361). Conversely, in clopidogrel-treated patients, a statistically significant lower total plasma exposure (AUC) of clopidogrel active metabolite was observed in RMs compared to those with CYP2C19 EM status (P = 0.0015; Figures 1 and 2). Exposure for prasugrel active metabolite was higher for the prasugrel EM group compared with the clopidogrel EM group (P = 0.000). That is, the active metabolite exposure following the prasugrel 60 mg LD was higher than after the clopidogrel 600 mg LD even when the comparison was limited to patients with normal CYP2C19 activity as predicted by genotype.
###end p 46
###begin p 47
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
Comparison of prasugrel 60 mg and clopidogrel 600 mg loading dose exposure of active metabolite by CYP2C19 genetic classification. Box represents median, 25th, and 75th percentiles and whiskers represent the most extreme values within 1.5 times inter-quartile range of the box. AUC, area under the concentration-time curve; EM, extensive metabolizer; RM, reduced metabolizer.
###end p 47
###begin p 48
###xml 91 114 91 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19, CYP2B6, CYP2C9</italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
Ratio RM/EM or difference (EM - RM) for pharmacokinetics and pharmacodynamic responses for CYP2C19, CYP2B6, CYP2C9, and CYP3A5. Mean and 95% confidence interval for ratio (AUC at LD) or difference (VASP-PRI at 24 h post-LD and MD Day 14 and Day 29) is derived from a linear model and is plotted for each CYP gene. AUC, area under the concentration-time curve; EM, extensive metabolizer; LD, loading dose; MD, maintenance dose; RM, reduced metabolizer; VASP, vasodilator-stimulated phosphoprotein; PRI, platelet reactivity index.
###end p 48
###begin title 49
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
Relationship between pharmacodynamic response and CYP2C19
###end title 49
###begin p 50
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F3">3</xref>
###xml 182 191 182 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="EHP157F3">3</xref>A</italic>
###xml 256 259 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 284 285 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F3">3</xref>
###xml 277 286 268 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="EHP157F3">3</xref>B</italic>
###xml 357 360 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 387 394 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
In clopidogrel-treated patients, patients with CYP2C19 RM genotypes exhibited a reduced pharmacodynamic response, as measured by VASP, compared with those with CYP2C19 EM genotypes (Figure 3A). Similar results were seen with the point-of-care device VerifyNowtrade mark P2Y12 (Figure 3B). This difference was not seen for either the VASP assay or the VerifyNowtrade mark P2Y12 device in CYP2C19 EM and RM in patients treated with prasugrel.
###end p 50
###begin p 51
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
###xml 147 148 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 288 290 279 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
Relationship between pharmacodynamic responses and CYP2C19 genetic classification measured by VASP assay (A) and VerifyNowtrade mark P2Y12 device (B). EM, extensive metabolizer; RM, reduced metabolizer; VASP, vasodilator-stimulated phosphoprotein; PRI, platelet reactivity index; PRU, P2Y12 reaction unit.
###end p 51
###begin title 52
Relationship between pharmacokinetics/pharmacodynamics and other analysed CYP P450 genes
###end title 52
###begin p 53
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2B6</italic>
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F2">2</xref>
###xml 153 161 153 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="EHP157F2">2</xref></italic>
###xml 273 275 273 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="EHP157F2">2</xref>
###xml 411 419 411 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="EHP157F2">2</xref></italic>
###xml 430 433 430 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Now</italic>
For CYP2C9, CYP2B6, and CYP3A5, there was no statistically significant effect of genotype on the exposure to active metabolite exposure for either drug (Figure 2). Accordingly, as expected, given the strong relationship between levels of active metabolite and degree of P2Y12 inhibition, analyses on their pharmacodynamic responses illustrated no statistically significant effect on PRI measured by VASP assay (Figure 2) or VerifyNowtrade mark P2Y12 device.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C10">10</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C12">12</xref>
###xml 486 491 486 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C10">10</xref>,<xref ref-type="bibr" rid="EHP157C12">12</xref></sup>
###xml 1054 1063 1054 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*2</italic>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C16">16</xref>
###xml 1221 1223 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C19">19</xref>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C28">28</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C29">29</xref>
###xml 1218 1229 1218 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C16">16</xref>,<xref ref-type="bibr" rid="EHP157C19">19</xref>,<xref ref-type="bibr" rid="EHP157C28">28</xref>,<xref ref-type="bibr" rid="EHP157C29">29</xref></sup>
###xml 1257 1264 1257 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 659 666 <span type="species:ncbi:9606">patient</span>
###xml 967 974 <span type="species:ncbi:9606">patient</span>
The results of this study support the hypothesis that a decrease in CYP2C19 function reduces the formation of clopidogrel's active metabolite, resulting in less inhibition of platelet function. In contrast, decreased CYP2C19 function does not appear to affect the exposure to prasugrel's active metabolite or the resulting inhibition of platelet function. These findings in a cohort of aspirin-treated patients with CAD confirm the previously described observations in healthy subjects.10,12 Of note, this genetic effect was even evident following the higher, 600 mg clopidogrel LD and persisted throughout the 75 mg MD phase. These results demonstrate, in a patient cohort, that genetic variation resulting in decreased CYP function partly accounts for poor pharmacodynamic response to clopidogrel and lower exposure to clopidogrel active metabolite. Our findings confirm the critical link between exposure to active metabolite and subsequent platelet response in a patient population. Our data also agree well with results reported by others where the CYP2C19*2 allele was associated with a higher on-clopidogrel platelet reactivity which in turn has been linked to worsened clinical outcome after coronary stenting.16,19,28,29 The effect of variation in CYP2C19 on responsiveness to clopidogrel complicates the prescribing of thienopyridines.
###end p 55
###begin p 56
###xml 17 27 17 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19 RM</italic>
###xml 199 208 199 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*2</italic>
###xml 237 244 237 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C30">30</xref>
###xml 303 305 303 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C30">30</xref></sup>
###xml 330 339 330 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*2</italic>
###xml 480 487 480 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C18">18</xref>
###xml 561 563 561 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C18">18</xref></sup>
The frequency of CYP2C19 RM genotypes shows wide inter-ethnic variation, ranging from 20-30% in Caucasians to 35-45% in African-Americans and 50-65% in East Asians. The most common defective allele, CYP2C19*2, accounts for 75-85% of the CYP2C19 alleles responsible for RMs in Caucasians and East Asians.30 The ethnic variation in CYP2C19*2 is likely one of the causes for inter-ethnic differences in the pharmacokinetics of several widely prescribed drugs that are substrates for CYP2C19 and also suggests that the response to clopidogrel may vary by ethnicity.18
###end p 56
###begin p 57
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 257 265 257 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 322 329 322 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 372 379 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 631 638 631 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 677 684 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 724 731 724 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 1173 1174 1173 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C9">9</xref>
###xml 1173 1174 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C9">9</xref></sup>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
In the present trial, the results were potentially confounded by the nearly 20% of patients (17 of 98) who were taking medications known to inhibit CYP function (14 of these patients were taking CYP2C19 inhibitors such as omeprazole and lansoprazole). In a post hoc analysis, patients receiving medication purported to be CYP2C19 inhibitors were grouped together with the CYP2C19 RM genetic group. The difference in pharmacokinetic and pharmacodynamic response to clopidogrel between the modified EM and RM groups was even more apparent (data not shown). For prasugrel, no such trend was observed when patients receiving potential CYP2C19-inhibitor drugs were grouped with the CYP2C19 RM group. In addition to inhibition of CYP2C19, another possible mechanism for drug-interaction with proton pump inhibitors (PPI) is alteration in gastric pH, which could affect thienopyridine absorption. In a recent cross-over study, increasing gastric pH with lansoprazole did not decrease the level of platelet inhibition after a prasugrel 60 mg LD, while in contrast in the same subjects lansoprazole did tend to dampen the antiplatelet response observed with a clopidogrel 300 mg LD.9
###end p 57
###begin p 58
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C27">27</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C31">31</xref>
###xml 129 134 129 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C27">27</xref>,<xref ref-type="bibr" rid="EHP157C31">31</xref></sup>
###xml 328 330 328 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 384 391 384 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 503 504 503 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 538 540 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 648 650 648 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 645 650 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P2Y<sub>12</sub></italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C29">29</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C32">32</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C34">34</xref>
###xml 738 746 738 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C29">29</xref>,<xref ref-type="bibr" rid="EHP157C32">32</xref>&#8211;<xref ref-type="bibr" rid="EHP157C34">34</xref></sup>
###xml 770 772 770 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 926 934 926 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 939 941 939 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C35">35</xref>
###xml 1024 1026 1024 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C35">35</xref></sup>
###xml 1193 1195 1193 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1219 1220 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C7">7</xref>
###xml 1219 1220 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C7">7</xref></sup>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
Both clopidogrel- and prasugrel-active metabolites show similar antiplatelet activity and exposure-pharmacodynamic relationships.27,31 We have previously reported a strong correlation between plasma concentrations of active metabolite and platelet inhibition for both prasugrel and clopidogrel up to saturation levels of the P2Y12 receptor.7 Addition of clopidogrel active metabolite ex vivo resulted in maximal platelet inhibition, even in subjects previously classified as clopidogrel poor responders.7 Although polymorphisms of the P2Y12 receptor have been associated with different degrees of platelet aggregation in healthy volunteers, the P2Y12 H2 haplotype has not been proven to modulate clopidogrel response in patients with CAD.29,32-34 In addition, as the P2Y12 receptor is the target for both prasugrel and clopidogrel and the active metabolite of prasugrel and clopidogrel have been shown to be nearly equipotent in vitro, P2Y12 receptor variants would likely have similar effects on the response to both drugs.35 Together, these data strongly suggest that a poor pharmacodynamic response to clopidogrel is caused by ineffective generation of the active metabolite rather than P2Y12 receptor heterogeneity.7
###end p 58
###begin p 59
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C14">14</xref>
###xml 518 520 518 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C14">14</xref></sup>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C36">36</xref>
###xml 727 729 727 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C36">36</xref></sup>
For clopidogrel, only a fraction of the prodrug is converted to the active metabolite in two sequential CYP-dependent steps. For prasugrel, the prodrug is rapidly converted first to an intermediate by esterases and then in one single CYP-dependent step to the active metabolite. Consequently, variation in the function of individual CYP-enzymes is not likely to affect the generation of the prasugrel active metabolite since any of the several CYPs can mediate the oxidation of the intermediate thiolactone metabolite.14 For clopidogrel on the other hand, with approximately 85% of the prodrug converted to the inactive metabolite, even small changes on CYP enzyme activity seem to influence formation of its active metabolite.36
###end p 59
###begin p 60
###xml 313 320 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C37">37</xref>
###xml 509 511 509 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C37">37</xref></sup>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C38">38</xref>
###xml 728 730 728 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C38">38</xref></sup>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 606 614 <span type="species:ncbi:9606">patients</span>
Changes in CYP enzyme activity are known to be related to both genetic variants that result in decreased CYP function and the use of concomitant CYP-inhibitory drugs. For example, as previously reported, patients randomized to clopidogrel and aspirin co-administered with omeprazole, a drug capable of inhibiting CYP2C19, had a significantly decreased platelet inhibitory effect, and the risk of being classified as a poor responder was 4.31 times greater compared with patients treated only with clopidogrel.37 These results are consistent with the recently presented findings of the MedCo study in which patients taking both clopidogrel and PPIs experienced a higher rate of cardiac events than those taking clopidogrel alone.38
###end p 60
###begin p 61
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C39">39</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C41">41</xref>
###xml 327 332 327 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C39">39</xref>&#8211;<xref ref-type="bibr" rid="EHP157C41">41</xref></sup>
###xml 412 422 412 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4/3A5</italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A</italic>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C15">15</xref>
###xml 582 584 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C15">15</xref></sup>
###xml 736 742 736 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C10">10</xref>
###xml 946 948 946 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C10">10</xref></sup>
###xml 927 934 <span type="species:ncbi:9606">patient</span>
When examining other CYPs, no statistically significant association was found between genetic variants and the response to thienopyridines, clopidogrel, or prasugrel. The effect on clopidogrel's antiplatelet response by CYP3A substrates, such as lipophilic statins, has been debated, and the results reported are contradictory.39-41 In a cross-over study on healthy subjects, ketoconazole, a potent inhibitor of CYP3A4/3A5 and representing a 'worst-case' interaction for CYP3A substrates, was shown to decrease the exposure to the active metabolite of clopidogrel but not prasugrel.15 As the clinical implication remains uncertain, further investigation on interactions of lipophilic statins with thienopyridine treatment is warranted. CYP2C9 loss-of-function genotypes have been associated with decreased exposure to the active metabolite for clopidogrel but not prasugrel; however, this observation was not confirmed in this patient population.10
###end p 61
###begin title 62
Study limitations
###end title 62
###begin p 63
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1A2</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A</italic>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C15">15</xref>
###xml 540 542 540 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C15">15</xref></sup>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A</italic>
###xml 664 670 664 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 754 760 754 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5</italic>
###xml 1148 1154 1148 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A4</italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Some limitations in this study need to be addressed. Because of sample size we did not observe sufficient numbers of patients with decreased function polymorphisms for CYP3A4 and CYP1A2 to evaluate a possible relationship to decreased thienopyridine response. Nonetheless, decreased function polymorphisms of these CYPs are uncommon. CYP1A2 is not involved in prasugrel metabolism. The CYP3A system is known to be involved in the metabolism of both drugs, and inhibition has been demonstrated to result in decreased exposure to clopidogrel.15 The role of individual CYP3A genes in thienopyridine activation is complicated by the known compensatory actions between CYP3A4 and CYP3A5. Furthermore, the low frequency of variants in all ethnic subgroups for CYP3A4 and the high degree of null variants in CYP3A5 do not directly correlate with the level of clopidogrel unresponsiveness. Thus, variants in these genes are unlikely to play a clinically meaningful role in variable response to clopidogrel or prasugrel. However, although variants with established functional effect were measured, further investigation is warranted as not all variants for CYP3A4 were tested in the current study.
###end p 63
###begin p 64
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C18">18</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C20">20</xref>
###xml 281 286 281 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C18">18</xref>,<xref ref-type="bibr" rid="EHP157C20">20</xref></sup>
###xml 413 420 413 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 688 697 688 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19*2</italic>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C16">16</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C19">19</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C28">28</xref>
###xml 833 841 833 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C16">16</xref>,<xref ref-type="bibr" rid="EHP157C19">19</xref>,<xref ref-type="bibr" rid="EHP157C28">28</xref></sup>
###xml 941 948 941 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C19">19</xref>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C28">28</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="EHP157C29">29</xref>
###xml 1058 1066 1058 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="EHP157C19">19</xref>,<xref ref-type="bibr" rid="EHP157C28">28</xref>,<xref ref-type="bibr" rid="EHP157C29">29</xref></sup>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
We grouped genotypes characterized as moderately reduced and those with essentially no reported activity into a single group, RM. Although essential for power, we therefore could not assess whether there was a 'gene dose-effect' for either the response to prasugrel or clopidogrel.18,20 A larger study population would allow for further discrimination between those with moderately reduced and those with ablated CYP2C19 function. In addition, as subjects in this study were not followed long-term to collect clinical outcome measures, it was not possible to establish a relationship between variation in the genes encoding CYP enzymes and clinical outcome. However, the loss-of-function CYP2C19*2 allele has been associated with high on-clopidogrel platelet reactivity, a phenotype that has been linked to a poorer clinical outcome.16,19,28 This observation has been re-inforced by three recent publications reporting that reduced function CYP2C19 genotypes were associated with an increased rate of clinical events in patients with acute coronary syndrome.19,28,29
###end p 64
###begin p 65
###xml 144 151 <span type="species:ncbi:9606">patient</span>
###xml 659 666 <span type="species:ncbi:9606">patient</span>
Despite the above stated limitations, this study represents, to our knowledge, the most comprehensive genotyping assessment ever completed on a patient population exposed to thienopyridines. Thus, this is the first time a comprehensive assay, assessing all the variation predicted to result in decreased function, in six of the genes involved in the metabolism of thienopyridines has been investigated. In addition to the uniqueness of the genotyping, this is the first time that variation in genes encoding CYP enzymes conferring reduced function has been directly linked to reduced pharmacokinetic exposure and also to reduced pharmacodynamic response in a patient population.
###end p 65
###begin p 66
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
###xml 165 167 165 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
This study showed that variation in the gene encoding CYP2C19 contributes to reduced exposure to clopidogrel's active metabolite and a corresponding reduction in P2Y12 inhibition, but has no influence on the response to prasugrel. The usefulness of assessment of this and other genetic polymorphisms for the selection of type and dose of thienopyridine needs further evaluation in clinical outcome trials.
###end p 66
###begin title 67
Funding
###end title 67
###begin p 68
###xml 0 30 0 30 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Daiichi Sankyo Company Limited</funding-source>
###xml 35 56 35 56 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eli Lilly and Company</funding-source>
Daiichi Sankyo Company Limited and Eli Lilly and Company (to Drs C.V., S.J., D.E., O.O.B., L.W., and A.S.). Funding to pay the Open Access publication charges for this article was provided by Daiichi Sankyo Company, Limited, Tokyo, Japan and Eli Lilly and Company, Indianapolis, IN, USA.
###end p 68
###begin p 69
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest:</bold>
Conflict of interest: J.T.B., S.L.C., M.M., and K.J.W. are employees and stockholders of Eli Lilly and Company. J.W. is an employee of Daiichi Sankyo Inc.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplementary Data]
###end title 71
###begin title 72
Acknowledgements
###end title 72
###begin p 73
The authors would like to thank Vivian Thieu for writing and administrative assistance (Eli Lilly and Company) and Julie Sherman for editorial assistance.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
###end article-title 75
###begin article-title 76
###xml 48 56 <span type="species:ncbi:9606">patients</span>
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute
###end article-title 76
###begin article-title 77
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
###end article-title 77
###begin article-title 78
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
###end article-title 78
###begin article-title 79
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
###end article-title 79
###begin article-title 80
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
###end article-title 80
###begin article-title 81
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
###end article-title 81
###begin article-title 82
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease (see comment)
###end article-title 82
###begin article-title 83
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
###end article-title 83
###begin article-title 84
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
###end article-title 84
###begin article-title 85
Identification and biological activity of the active metabolite of clopidogrel
###end article-title 85
###begin article-title 86
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
###end article-title 86
###begin article-title 87
The anti-aggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A
###end article-title 87
###begin article-title 88
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
###end article-title 88
###begin article-title 89
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
###end article-title 89
###begin article-title 90
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
###end article-title 90
###begin article-title 91
###xml 203 211 <span type="species:ncbi:9606">patients</span>
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
###end article-title 91
###begin article-title 92
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance
###end article-title 92
###begin article-title 93
Cytochrome P-450 polymorphisms and response to clopidogrel
###end article-title 93
###begin article-title 94
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
###end article-title 94
###begin article-title 95
Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine
###end article-title 95
###begin article-title 96
Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport
###end article-title 96
###begin article-title 97
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
###end article-title 97
###begin article-title 98
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects
###end article-title 98
###begin article-title 99
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Drug metabolism and variability among patients in drug response
###end article-title 99
###begin article-title 100
Rapid platelet-function assay: an automated and quantitative cartridge-based method
###end article-title 100
###begin article-title 101
Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response
###end article-title 101
###begin article-title 102
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
###end article-title 102
###begin article-title 103
Genetic determinants of response to clopidogrel and cardiovascular events
###end article-title 103
###begin article-title 104
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
###end article-title 104
###begin article-title 105
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
The greater in vivo antiplatelet effects of prasugrel compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to clopidogrel's active metabolite
###end article-title 105
###begin article-title 106
###xml 73 75 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
###end article-title 106
###begin article-title 107
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose
###end article-title 107
###begin article-title 108
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease
###end article-title 108
###begin article-title 109
###xml 30 35 <span type="species:ncbi:9606">human</span>
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor
###end article-title 109
###begin article-title 110
Pharmacokinetics of clopidogrel
###end article-title 110
###begin article-title 111
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
###end article-title 111
###begin article-title 112
Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study
###end article-title 112
###begin article-title 113
Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study
###end article-title 113
###begin article-title 114
Effects of statins on platelet inhibition by a high loading dose of clopidogrel
###end article-title 114
###begin article-title 115
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
###end article-title 115

